ProNAi Therapeutics (DNAI) : During the past 4 weeks, traders have been relatively bearish on ProNAi Therapeutics (DNAI), hence the stock is down -7.42% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.58% relative to the S&P 500. The 4-week change in the price of the stock is -6.47% and the stock has fallen -5.53% in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.43% and the 50-Day Moving Average is 13.74%. ProNAi Therapeutics (NASDAQ:DNAI): On Fridays trading session , Opening price of the stock was $1.88 with an intraday high of $1.94. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.87. However, the stock managed to close at $1.88, a loss of 2.08% for the day. On the previous day, the stock had closed at $1.92. The total traded volume of the day was 525,848 shares.
The company Insiders own 22.2% of ProNAi Therapeutics shares according to the proxy statements. Institutional Investors own 62.15% of ProNAi Therapeutics shares. Also, In a research note released to the investors, Jefferies downgrades its rating on ProNAi Therapeutics (NASDAQ:DNAI).The analysts at the brokerage house have a current rating of Hold on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 6, 2016.
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.